Recent Updates
Recently added Catalysts
CGON Positive Sentiment

NATURE MEDICINE

Monday, November 11, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the phase 2 CORE-001 trial, which investigates the efficacy of oncolytic adenoviral therapy combined with pembrolizumab for patients with BCG-unresponsive non-muscle-invasive bladder cancer. The trial aims to provide new treatment options for this challenging patient population. Recent results suggest positive outcomes, indicating a potential advancement in bladder cancer therapy.
Price reaction · baseline $39.94 (2024-11-08 close) · hit pre-market · 1 other CGON headline(s) in the window, move may be shared
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Oncolytic adenoviral therapy shows promise in treating bladder cancer.
  • CORE-001 trial indicates potential benefits for BCG-unresponsive patients.
  • Combination therapy may enhance treatment outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Nov 11, 2024 | in-the-news
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What is the CORE-001 trial about?

The CORE-001 trial studies oncolytic adenoviral therapy combined with pembrolizumab for BCG-unresponsive bladder cancer.

What type of cancer is being targeted in the trial?

The trial targets non-muscle-invasive bladder cancer that is unresponsive to BCG treatment.

What are the potential benefits of this therapy?

The therapy may provide new treatment options and improve outcomes for patients with challenging bladder cancer.

Who is conducting the CORE-001 trial?

The trial is conducted by CG Oncology, focusing on innovative cancer therapies.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology bladder cancer BCG-unresponsive oncolytic therapy pembrolizumab
Last updated: Nov 11, 2024

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →